Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population. [electronic resource]
Producer: 20161213Description: 232-6 p. digitalISSN:- 1533-4023
- Adenosine -- adverse effects
- Aged
- Aged, 80 and over
- Asian People -- genetics
- Biotransformation
- Chi-Square Distribution
- China
- Clopidogrel
- Coronary Artery Disease -- ethnology
- Cytochrome P-450 CYP2C19 -- genetics
- Drug Monitoring -- methods
- Female
- Genotype
- Hemorrhage -- chemically induced
- Humans
- Logistic Models
- Male
- Middle Aged
- Multivariate Analysis
- Odds Ratio
- Percutaneous Coronary Intervention -- adverse effects
- Pharmacogenomic Testing
- Phenotype
- Platelet Aggregation Inhibitors -- adverse effects
- Platelet Function Tests
- Polymorphism, Genetic
- Risk Factors
- Ticagrelor
- Ticlopidine -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.